Close Menu

NEW YORK – RenalytixAI and AstraZeneca have signed an agreement to develop and launch precision medicine strategies for cardiovascular, rental, and metabolic diseases.

Working with the Mount Sinai Health System, the firms plan to use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease (CKD) and its complications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.